Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
OPKO Health Inc (OPK) Insider Trading Activity
Healthcare • Diagnostics & Research • 3,930 employees
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.
Total Value
-$4,595,537.20
Total Shares
1,777,194
Average Trade Value
-$328,252.66
Most Active Insider
Opko Health, Inc.
Total Activity: $7,655,189
Largest Single Transaction
$2,029,811
by Opko Health, Inc. on Aug 12, 2024
30-Day Activity
3 Transactions
Volume: 697,537 shares
Value: $1,031,335
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
CEO Chairman
|
Jan 28, 2025 | 47,537 | $70,060 | 213,234,014 (+0.0%) | Purchase | |
CEO Chairman
|
Jan 17, 2025 | 150,000 | $220,425 | 213,186,477 (+0.1%) | Purchase | |
CEO Chairman
|
Jan 15, 2025 | 500,000 | $740,850 | 213,036,477 (+0.2%) | Purchase | |
CEO Chairman
|
Dec 13, 2024 | 125,000 | $199,375 | 212,536,477 (+0.1%) | Purchase | |
CEO Chairman
|
Dec 11, 2024 | 500,000 | $781,050 | 212,411,477 (+0.2%) | Purchase | |
CEO Chairman
|
Nov 29, 2024 | 199,072 | $305,376 | 211,911,477 (+0.1%) | Purchase | |
CEO Chairman
|
Nov 22, 2024 | 100,000 | $159,000 | 211,712,405 (+0.0%) | Purchase | |
CEO Chairman
|
Nov 14, 2024 | 100,000 | $161,980 | 211,612,405 (+0.0%) | Purchase | |
CEO Chairman
|
Nov 8, 2024 | 280,183 | $421,535 | 211,512,405 (+0.1%) | Purchase | |
Aug 19, 2024 | 50,000 | $1,724,520 | 2,646,972 (-1.9%) | Sale | ||
Aug 16, 2024 | 50,000 | $1,714,850 | 2,696,972 (-1.9%) | Sale | ||
Aug 15, 2024 | 39,824 | $1,317,505 | 2,746,972 (-1.4%) | Sale | ||
Aug 13, 2024 | 24,987 | $868,503 | 2,786,796 (-0.9%) | Sale | ||
Aug 12, 2024 | 59,787 | $2,029,811 | 2,811,783 (-2.1%) | Sale |